Edwin Roger Parra Cuentas
Edwin Roger Parra Cuentas
Dr. Faculdade de Medicina da Universidade de São Paulo
Overená e-mailová adresa na:
Citované v
Citované v
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
Cancer discovery 5 (8), 860-877, 2015
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ...
The Lancet Oncology 21 (11), 1413-1422, 2020
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Y Wang, DH Wiesnoski, BA Helmink, V Gopalakrishnan, K Choi, ...
Nature medicine 24 (12), 1804-1808, 2018
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ...
Nature medicine 27 (3), 504-514, 2021
A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition
MP Mak, P Tong, L Diao, RJ Cardnell, DL Gibbons, WN William, ...
Clinical Cancer Research 22 (3), 609-620, 2016
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
ER Parra, N Uraoka, M Jiang, P Cook, D Gibbons, MA Forget, ...
Scientific reports 7 (1), 13380, 2017
Association of interferon‐and transforming growth factor β–regulated genes and macrophage activation with systemic sclerosis–related progressive lung fibrosis
RB Christmann, P Sampaio‐Barros, G Stifano, CL Borges, ...
Arthritis & rheumatology 66 (3), 714-725, 2014
A proteogenomic portrait of lung squamous cell carcinoma
S Satpathy, K Krug, PMJ Beltran, SR Savage, F Petralia, C Kumar-Sinha, ...
Cell 184 (16), 4348-4371. e40, 2021
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
H Kadara, M Choi, J Zhang, ER Parra, J Rodriguez-Canales, SG Gaffney, ...
Annals of Oncology 28 (1), 75-82, 2017
The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
JM Taube, G Akturk, M Angelo, EL Engle, S Gnjatic, S Greenbaum, ...
Journal for immunotherapy of cancer 8 (1), 2020
TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence
A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ...
Cancer discovery 7 (10), 1088-1097, 2017
Comprehensive T cell repertoire characterization of non-small cell lung cancer
A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ...
Nature communications 11 (1), 603, 2020
Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non–small cell lung carcinoma
ER Parra, P Villalobos, B Mino, J Rodriguez-Canales
Applied Immunohistochemistry & Molecular Morphology 26 (2), 83-93, 2018
Image analysis–based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non–small cell lung carcinoma patients
ER Parra, C Behrens, J Rodriguez-Canales, H Lin, B Mino, J Blando, ...
Clinical Cancer Research 22 (24), 6278-6289, 2016
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
External Resources Crossref (DOI), 2012
Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab
EZ Keung, M Burgess, R Salazar, ER Parra, J Rodrigues-Canales, ...
Clinical Cancer Research 26 (6), 1258-1266, 2020
Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches
ER Parra, P Villalobos, C Behrens, M Jiang, A Pataer, SG Swisher, ...
Journal for immunotherapy of cancer 6, 1-11, 2018
Development of an immune-pathology informed radiomics model for non-small cell lung cancer
C Tang, B Hobbs, A Amer, X Li, C Behrens, JR Canales, EP Cuentas, ...
Scientific reports 8 (1), 1922, 2018
Multiplatform-based molecular subtypes of non-small-cell lung cancer
F Chen, Y Zhang, E Parra, J Rodriguez, C Behrens, R Akbani, Y Lu, ...
Oncogene 36 (10), 1384-1393, 2017
Systém momentálne nemôže vykonať operáciu. Skúste to neskôr.
Články 1–20